Edwards Lifesciences Comments on U.S. Appeals Court Order

Edwards Lifesciences Comments on U.S. Appeals Court Order 
IRVINE, CA -- (Marketwired) -- 04/21/14 --  Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, announced that the U.S. Court of
Appeals for the Federal Circuit today issued a stay for the
preliminary injunction that was ordered on April 11 to limit the sale
of Medtronic's CoreValve system in the United States. According to
the court's two-to-one decision, the injunction has been placed on
hold "pending further notice."  
"We have always made every effort to ensure patients receive the
treatment they need and will continue to seek a durable solution that
benefits physicians and their patients. We're proud of the track
record and large amount of clinical data supporting the performance
of the SAPIEN family of valves, making them the preferred choice for
doctors treating their patients around the world," said Michael A.
Mussallem, Edwards' chairman and CEO.  
Today's order postpones the implementation of the preliminary
injunction. It does not reverse the federal jury's finding of
Medtronic's willful infringement, for which all appeals have been
exhausted, and does not affect the determination of additional
damages.  
About Edwards Lifesciences
 Edwards Lifesciences is the global leader
in the science of heart valves and hemodynamic monitoring. Driven by
a passion to help patients, the company partners with clinicians to
develop innovative technologies in the areas of structural heart
disease and critical care monitoring, enabling them to save and
enhance lives. Additional company information can be found at
www.edwards.com.  
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, Mr. Mussallem's comments.
Forward-looking statements are based on estimates and assumptions
made by management of the company and are believed to be reasonable,
though they are inherently uncertain and difficult to predict. Our
forward-looking statements speak only as of the date on which they
are made and we do not undertake any obligation to update any
forward-looking statem
ent to reflect events or circumstances after
the date of the statement.  
Forward-looking statements involve risks and uncertainties that could
cause the roll-out and benefits of the technology to differ
materially from those expressed or implied by the forward-looking
statements based on a number of factors including but not limited to
unexpected outcomes after expanded clinical experience, unexpected
changes or delays related to product supply, quality and
availability, or unanticipated delays or outcomes in regulatory
approvals and decisions. These factors are detailed in the company's
filings with the Securities and Exchange Commission including its
Annual Report on Form 10-K for the year ended December 31, 2013. 
Edwards, Edwards Lifesciences, the stylized E logo and SAPIEN are
trademarks of Edwards Lifesciences Corporation. All other trademarks
are the property of their respective owners. 
Media Contact: 
Sarah Huoh
949-250-5070 
Investor Contact:
David K. Erickson
949-250-6826 
 
 
Press spacebar to pause and continue. Press esc to stop.